Comparison of Quadratus Lumborum Intramuscular and Transmuscular in Postoperative Pain

Sponsor
Udayana University (Other)
Overall Status
Completed
CT.gov ID
NCT05005871
Collaborator
(none)
48
1
2
1.4
34

Study Details

Study Description

Brief Summary

Acute pain is reported in approximately 80% of patients undergoing postoperative care for various types of surgical procedures in the United States. Another study reported patient postoperative pain intensity with 75% with severe pain in the first 1 to 2 postoperative days and 38% reporting moderate to severe pain at 14 postoperative days. Several modalities have been used as the standard for the management of pain postoperative C-sections.

One of the postoperative analgesic modalities for SC is quadratus lumborum block (QLB). This technique has advantages in relieving postoperative pain after C-section because it is considered to be able to relieve visceral pain as well as somatic pain. The transmuscular QLB (QLBT) approach is one of the most frequently used. This technique was found to be effective with regard to the distribution of analgesics to the paravertebral spaces which is the hallmark of QLB. However, this technique was found to be difficult to perform. Difficulties were reported related to the position of the procedure i.e. lateral or sitting position.

Condition or Disease Intervention/Treatment Phase
  • Other: Quadratus lumborum block after C-section surgery as postoperative pain management
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of the Effectiveness of Intramuscular and Transmucular Quadratus Lumborum Blocks Quality in Postoperative Pain
Actual Study Start Date :
Sep 1, 2021
Actual Primary Completion Date :
Sep 30, 2021
Actual Study Completion Date :
Oct 14, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Quadratus lumborum intramuscular block

The quadratus lumborum intramuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.

Other: Quadratus lumborum block after C-section surgery as postoperative pain management
To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.

Active Comparator: Quadratus lumborum transmucular block

The quadratus lumborum transmuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.

Other: Quadratus lumborum block after C-section surgery as postoperative pain management
To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.

Outcome Measures

Primary Outcome Measures

  1. Postoperative pain [Up to 24 hours after surgery]

    Postoperative pain intensity measured by Visual Analog Scale (VAS), 0=no pain, 100=worst pain

  2. Postoperative morphine requirements [Up to 72 hours after surgery]

    Total delivered morphine dose after surgery to alleviate postoperative pain (measured by total delivered dose recorded on the Patient-Controlled Analgesia tool)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Underwent C-section with subarachnoid block

  • Aged 18-35 years old.

  • ASA preoperative physical status 1-2

Exclusion Criteria:
  • Coagulopathy

  • Anatomic abnormalities of the abdomen

  • History of allergy to local anesthesia

  • History of hyperalgesia

  • History of drug abuse (sedatives, opioids, paracetamol, or other pain relievers)

  • Require postoperative intensive care

  • Refuse to participate in research.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sanglah General Hospital Denpasar Bali Indonesia 80114

Sponsors and Collaborators

  • Udayana University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christopher Ryalino, MD, Principal Investigator, Udayana University
ClinicalTrials.gov Identifier:
NCT05005871
Other Study ID Numbers:
  • UNUD-CTR-FK150621-001
First Posted:
Aug 16, 2021
Last Update Posted:
Oct 19, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 19, 2021